EFL068
For our 68th episode, we look at a paper in The Journal of Clinical Endocrinology & Metabolism that compares the effect on calcium of initial and subsequent doses of denosumab in people with chronic kidney disease (CKD). Though concerns have arisen over the years about the problems with stopping denosumab therapy, it remains an appealing medication for some of our patients with CKD. So we thought this report had the potential to change our practice and gave us the opportunity to delve into the challenges around osteoporosis in CKD. Host Chase Hendrickson, MD, MPH, MHCC, from Vanderbilt University talks with regular contributor Amal Shibli-Rahhal, MD, from University of Iowa Carver College of Medicine, and guest expert Kristin Clemens, MD, from St. Joseph’s Hospital and Western University in London, Ontario, Canada. They discuss “Dose-Specific Effects of Denosumab on Serum Calcium Levels in Patients With Osteoporosis and Various Renal Functions” by Sun et al, published in the July 2025 issue of JCEM.
Meet the Speakers
Kristin Clemens, MD, is a clinician-scientist and associate professor of medicine and epidemiology and biostatistics at Western University in London, Ontario, Canada. She practices as a general endocrinologist at St. Joseph’s Health Care London and is medical director of the Osteoporosis and Metabolic Bone Disease Program. Dr. Clemens is an active health services and disparities researcher with diverse methodological experience. Her osteoporosis research focuses upon improving the care and outcomes of those with osteoporosis and metabolic disease including diabetes and cardiovascular kidney metabolic syndrome.
Amal Shibli-Rahhal, MD, MSc, MME, received her medical degree from the American University of Beirut and completed her post-graduate training in internal medicine and endocrinology at the University of Iowa. Dr. Shibli-Rahhal is professor and endocrinologist at the University of Iowa, where she also acts as the Associate Dean for Student Affairs and Curriculum at the University of Iowa Carver College of Medicine. Previously, Dr. Shibli-Rahhal acted as Endocrinology Fellowship Program Director, preclinical Course Director for the College of Medicine, and Associate Chief of Staff for Education at the Iowa City VA. In addition to her role as program director, Dr. Shibli-Rahhal also created and serves as Director of the University of Iowa Metabolic Bone Clinic.
Everything said on the podcast represents individuals’ opinions only and not those of the participants’ institutions or of the Endocrine Society.
Resources
Meet the Host
Chase Hendrickson, MD, MPH, MMHC, practices general endocrinology at the Vanderbilt University Medical Center, where he is an associate program director for the endocrinology fellowship program. His interests include endocrine education, teaching inferential methods, and quality improvement.
Subscribe
Stay up to date by copying the following into your podcast player:
https://www.endocrine.org/-/media/endosociety/files/podcasts/efl/efl.xml
Or you can find us on the following streaming services:
